Cargando…

Corrigendum to “Network meta-analysis of immune-oncology monotherapy as first-line treatment for advanced non-small-cell lung cancer in patients with PD-L1 expression ⩾50%”

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2022
Materias:	Corrigendum
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9478690/ https://www.ncbi.nlm.nih.gov/pubmed/36119642 http://dx.doi.org/10.1177/17588359221127078

Ejemplares similares

Network meta-analysis of immune-oncology monotherapy as first-line treatment for advanced non-small-cell lung cancer in patients with PD-L1 expression ⩾50%
por: Freemantle, Nick, et al.
Publicado: (2022)

Corrigendum to ‘The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 ≥ 50% advanced non-small-cell lung cancer’: [ESMO Open Volume 6, Issue 2, April 2021, 100078]
por: Banna, G.L., et al.
Publicado: (2021)

Effect of first-line endocrine therapy in patients with hormone-sensitive advanced breast cancer: a network meta-analysis [Corrigendum]
Publicado: (2018)

Agomelatine as monotherapy for major depression: an outpatient, open-label study [Corrigendum]
Publicado: (2013)

First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis
por: Liu, Qiao, et al.
Publicado: (2021)

Corrigendum to “Outcomes of Programmed Cell Death Protein 1 (PD-1) and Programmed Death-Ligand 1 (PD-L1) Inhibitor Therapy in HIV Patients with Advanced Cancer”
por: Bari, Shahla, et al.
Publicado: (2019)

Corrigendum to “Efficacy and Safety of First-Line Immunotherapy in Combination with Chemotherapy for Patients with Extensive-Stage Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis”
por: Wang, Bi-Cheng, et al.
Publicado: (2021)

PD-L1 Biomolecules Associated with Clinical Features in Non-Melanoma Skin Cancer [Corrigendum]
Publicado: (2023)

Patient‐reported outcomes with cemiplimab monotherapy for first‐line treatment of advanced non–small cell lung cancer with PD‐L1 of ≥50%: The EMPOWER‐Lung 1 study
por: Gümüş, Mahmut, et al.
Publicado: (2022)

Corrigendum to Artificial Intelligence in the Era of Precision Oncological Imaging
Publicado: (2023)

Corrigendum to “Different Presentation and Outcomes in the Surgical Treatment of Advanced MRONJ in Oncological and Nononcological Patients Taking or Not Corticosteroid Therapy”
por: Garzino-Demo, Paolo, et al.
Publicado: (2021)

Expression of B7-H3 Correlates with PD-L1 and Poor Prognosis in Patients with Cervical Cancer [Corrigendum]
Publicado: (2021)

Real-World Time on Treatment with First-Line Pembrolizumab Monotherapy for Advanced NSCLC with PD-L1 Expression ≥ 50%: 3-Year Follow-Up Data
por: Velcheti, Vamsidhar, et al.
Publicado: (2022)

Corrigendum to “Application of Minocycline-Containing Bismuth Quadruple Therapies as First-Line Regimens in the Treatment of Helicobacter pylori”
por: Zhang, Lingyun, et al.
Publicado: (2021)

miR-140-3p Suppresses Cell Growth and Induces Apoptosis in Colorectal Cancer by Targeting PD-L1 [Corrigendum]
Publicado: (2020)

The safety of first and subsequent lines of PD-1/PD-L1 inhibitors monotherapy in non-small cell lung cancer patients: a meta-analysis
por: Yang, Yilin, et al.
Publicado: (2020)

Baseline Serum Cholesterol Levels Predict the Response of Patients with Advanced Non-Small Cell Lung Cancer to Immune Checkpoint Inhibitor-Based Treatment [Corrigendum]
Publicado: (2022)

PD-1/PD-L1 Inhibitors as Monotherapy in the First-Line Treatment of Advanced Non-Small Cell Lung Cancer Patients with High PD-L1 Expression: An Expert Position Statement
por: Isla, Dolores, et al.
Publicado: (2023)

Corrigendum: IC50: an unsuitable measure for large-sized prostate cancer spheroids in drug sensitivity evaluation
Publicado: (2023)

CORRIGENDUM to Image Statistics and the Fine Lines of Material Perception
Publicado: (2016)

PD-(L)1 Inhibitors as Monotherapy for the First-Line Treatment of Non-Small-Cell Lung Cancer Patients with High PD-L1 Expression: A Network Meta-Analysis
por: Majem, Margarita, et al.
Publicado: (2021)

Network meta-analysis of first-line immune checkpoint inhibitor therapy in advanced non-squamous non-small cell lung cancer patients with PD-L1 expression ≥ 50%
por: Chen, Wei, et al.
Publicado: (2023)

Correction of acknowledgments: PD-L1 testing in non-small cell lung cancer: past, present, and future
por: Kim, Hyojin, et al.
Publicado: (2020)

Corrigendum to “Plant MicroRNA Prediction by Supervised Machine Learning Using C5.0 Decision Trees”
por: Williams, Philip H., et al.
Publicado: (2017)

Corrigendum to ‘Targeting P4HA1 with a Small Molecule Inhibitor in a Colorectal Cancer PDX Model’ [Translational Oncology 13 (2020) 100754]
por: Agarwal, Sumit, et al.
Publicado: (2021)

Corrigendum to “Advances of Techniques in Deep Regional Blocks”
por: Lin, Jui-An, et al.
Publicado: (2018)

Corrigendum to “Application of PK/PD Modeling in Veterinary Field: Dose Optimization and Drug Resistance Prediction”
por: Ahmad, Ijaz, et al.
Publicado: (2017)

Cost-Effectiveness Analysis of Gemtuzumab Ozogamicin for First-Line Treatment of Patients with Cd-33 Positive Acute Myeloid Leukaemia in Spain [Corrigendum]
Publicado: (2021)

Corrigendum to ‘Databases and Web Tools for Cancer Genomics Study’ [GPB 137 (2015) – GPB 13/1 (46–50)]
por: Yang, Yadong, et al.
Publicado: (2015)

PD-L1 Inhibitors as Monotherapy for the First-Line Treatment of Non-Small-Cell Lung Cancer in PD-L1 Positive Patients: A Safety Data Network Meta-Analysis
por: García Campelo, María Rosario, et al.
Publicado: (2021)

Investigation of response factors for monotherapy with immune checkpoint inhibitors in non‐small cell lung cancer patients with PD‐L1 expression <50%
por: Takahara, Yutaka, et al.
Publicado: (2023)

Corrigendum to ‘Combined gene essentiality scoring improves the prediction of cancer dependency maps’ [EBioMedicine 50 (2019) 66–79]
por: Wang, Wenyu, et al.
Publicado: (2020)

Corrigendum to ‘First-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus chemotherapy alone (4 cycles) in advanced non-small cell lung cancer: CheckMate 9LA 2-year update’: [ESMO Open Volume 6, Issue 5, October 2021, 100273]
por: Reck, M., et al.
Publicado: (2021)

Corrigendum to: Advances in plant reproduction: from gametes to seeds
por: Pereira, Ana Marta, et al.
Publicado: (2020)

Corrigendum: A first step toward understanding patient safety
por: Kim, Kyoung Ok
Publicado: (2017)

Corrigendum to: Idiopathic pleuroparenchymal fibroelastosis: first case report in Lebanon
por: Dbouk, Samer, et al.
Publicado: (2022)

Ocular comfort assessment of lifitegrast ophthalmic solution 5.0% in OPUS-3, a Phase III randomized controlled trial [Corrigendum]
Publicado: (2018)

Dengue infections in non-immune travellers to Thailand – CORRIGENDUM
por: MASSAD, E., et al.
Publicado: (2013)

Efficacy of PD-(L)1 blockade monotherapy compared with PD-(L)1 blockade plus chemotherapy in first-line PD-L1-positive advanced lung adenocarcinomas: a cohort study
por: Elkrief, Arielle, et al.
Publicado: (2023)

Corrigendum to “Recent Advances in Microwave Imaging for Breast Cancer Detection”
por: Kwon, Sollip, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_bo8m5e4n1emlsrjdev1nstccqh